UNDERWRITING AGREEMENTUnderwriting Agreement • June 27th, 2014 • Igi Laboratories, Inc • Biological products, (no disgnostic substances) • New York
IGI Laboratories, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Roth Capital Partners, LLC and Oppenheimer & Co. Inc. are acting as representatives (the “Representatives”), an aggregate of 4,650,000 authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.01 per share (the “Common Stock”), of the Company. The Company has granted the Underwriters the option to purchase an aggregate of up to 697,500 additional shares of Common Stock (the “Option Shares”) as may be necessary to cover over-allotments made in connection with the offering pursuant to Section 4(b) hereof. The Firm Shares and the Option Shares are collectively referred to as the “Shares.”
